Narayana Hrudayalaya comes to Gurugram, Acquires Panacea Biotec Hospital for Rs 180 crore

Published On 2017-04-22 07:01 GMT | Update On 2017-04-22 07:01 GMT

The company has “entered into a definitive agreement to acquire 100 per cent stake in NewRise Healthcare Pvt Ltd from Panacea Biotec Ltd to announce its first hospital in Gurugram”, Narayana Hrudayalaya said in a BSE filing.

New Delhi: Narayana Hrudayalaya has entered into an agreement with Panacea Biotec to fully acquire its subsidiary NewRise Healthcare for an enterprise value of Rs. 180 crore.

The company has “entered into a definitive agreement to acquire 100 per cent stake in NewRise Healthcare Pvt Ltd from Panacea Biotec Ltd to announce its first hospital in Gurugram”, Narayana Hrudayalaya said in a BSE filing.

NewRise Healthcare has set up a multi-speciality hospital in Gurugram which is in final stages of completion and is expected to be commissioned within the next nine months.

This transaction is intended to consolidate Narayana Hrudayalaya’s footprint in the northern cluster.

“This development is a step forward in the direction towards reinforcing the newly formed Northern cluster. It also echoes our group’s commitment towards developing this region as vibrant as the existing Karnataka and Eastern clusters,” Narayana Hrudayalaya Vice-Chairman, MD and Group CEO Ashutosh Raghuvanshi said.

The group believes its recent ventures in NCR will help it target this key region more efficiently while accelerating trajectory to become a true pan-India healthcare service provider, he added.

Medical Dialogues team had earlier reported that Narayana Hrudayalaya signed an agreement with Dharamshila Cancer Foundation and Research Centre for providing healthcare services.

Founded in 2000 by Devi Prasad Shetty, Narayana Hrudayalaya has a network of 23 hospitals and 7 heart centres across India and a single hospital overseas at Cayman Islands with over 5,700 operational beds across all its centres.

Shares of Narayana Hrudayalaya were trading 0.39 per cent lower at Rs. 317.10 per scrip, while Panacea Biotec’s stock was trading 3.58 per cent higher at Rs. 164.80 apiece on the BSE.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

savita

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .